Phase 1/2 × Paclitaxel × Sarcoma × Clear all
NCT05824975 2024-11-25

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

GI Innovation, Inc.

Phase 1/2 Recruiting
358 enrolled
NCT00004105 2011-03-28

Combination Chemotherapy in Treating Patients With Advanced Cancer

NYU Langone Health

Phase 1/2 Completed